Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Kurt Deshayes At The Challenges in Chemical Biology Conference | Main | More Behind-the-Scenes Maneuvering. How Wonderful. »

July 25, 2013

Ben Cravatt At The Challenges In Chemical Biology Conference

Email This Entry

Posted by Derek

Ben Cravatt is talking about this work on activity-based protein profiling of serine hydrolase enzymes. That's quite a class to work on - as he says, up to 2% of all the proteins in the body fall into this group, but only half of them have had even the most cursory bit of characterization. Even among the "known" ones, most of their activities are still dark, and only 10% of them have useful pharmacological tools.

He's detailed a compound (PF-3845) that Pfizer found as a screening hit for FAAH, which although it looked benign, turned out to be a covalent inhibitor due to a reactive arylurea. Pfizer, he says, backed off when this mechanism was uncovered - they weren't ready at the time for covalency, but he says that they've loosened up since then. Studying the compound in various tissues, including the brain, showed that it was extremely selective for FAAH.

Another reactive compound, JZL184, is an inhibitor of monoacylglycerol hydrolase (MAGL). Turns out that its carbamate group also reacts with FAAH, but there's a 300-fold window in the potency. The problem is, that's not enough. In mouse models, hitting both enzymes at the same time leads to behavioral problems. Changing the leaving group to a slightly less reactive (and nonaromatic) hexafluoroisopropanol, though, made the compound selective again. I found this quite interesting - most of the time, you'd think that 300x is plenty of room, but apparently not. That doesn't make things any easier, does it?

In response to a question (from me), he says that covalency is what makes this tricky. The half-life of the brain enzymes is some 12 to 14 hours, so by the time the next once-a-day dose comes in, there's still 20 or 30% of the enzyme still shut down, and things get out of hand pretty soon. For a covalent mechanism, he recommends 2000-fold or 5000-fold. On the other hand, he says that when they've had a serine hydrolase-targeted compound, they've never seen it react out of that class (targeting cysteine residues, though, is a very different story). And the covalent mechanism gives you some unique opportunities - for example, deliberate engineering a short half-life, because that might be all you need.

Comments (8) + TrackBacks (0) | Category: Chemical Biology | The Central Nervous System


COMMENTS

1. bad wolf on July 25, 2013 4:06 PM writes...

Wow, talking about papers from 2009 and 2008? I thought this was conference was 'current' challenges in Chem bio.

Permalink to Comment

2. ScientistSailor on July 25, 2013 7:00 PM writes...

Sanofi canned their covalent FAAH inhibitor due to lack of efficacy in the clinic. And it was just as potent/selective as Pfizer's...

Permalink to Comment

3. Derek Lowe on July 25, 2013 7:30 PM writes...

That was part one of the talk - there was newer stuff as it went on, fear not.

Permalink to Comment

4. bad wolf on July 25, 2013 9:03 PM writes...

Sorry, missed the 2012 paper. Glad to hear recent stuff is discussed--nothing more deflating than hearing history instead of news.

Permalink to Comment

5. SAR screener on July 26, 2013 6:24 AM writes...

Presumably with covalent inhibitors you need extremely good selectivity because once a cpd binds and reacts it’s stuck on the enzyme and so things like competition with substrate for your off target enzyme, which may save you in non-covalent systems are no longer effective.

How did they measure the selectivity?

IC50s can be misleading for covalent inhibitors as ultimately, if you leave them for long enough, all covalent inhibitors will have an IC50 of ½ [E].

Ranking by kinact/Ki gives a better idea of selectivity – it’s roughly analogous to using kcat/Km for comparing substrate selectivity, with kinact telling you how fast the compound reacts once it binds and Ki being a measure of affinity.

Permalink to Comment

6. Mark on July 26, 2013 5:26 PM writes...

I've worked extensively on FAAH inhibitors, and in particular, this same class of arylureas. I've also worked with Cravatts company that does the activity-based profiling. Its a great technique and provides a lot of insight into the potential off-target activity of this class.

Problem with this class of inhibitors is that potency doesn't correlate with efficacy. For all the papers that talk about URB597, there is a host of other drugs that are just as potent, if not moreso, that don't show any efficacy at all.

Permalink to Comment

7. weirdo on July 26, 2013 6:00 PM writes...

Mark: Re: efficacy & potency.

Why would one expect any relationship between "potency" and efficacy? For covalent inhibitors, as mentioned above, potency and selectivity are simply a matter of time. In addition, enzyme turnover is a feature often overlooked. Is it not possible for some covalent inhibitors to drive the target enzyme into a conformation that is more readily recognized by proteases (or other processing enzymes) and thus result in more rapid synthesis of new target protein? If one does not get the warhead electrophilicity just right, it may never have the chance to get to the target.

Lots of targets are going to great candidates for covalent warheads; those who figure that out early (and address/anticipate the new issues involved) are going to have a distinct advantage.

Permalink to Comment

8. anonymous on July 26, 2013 6:21 PM writes...

@5 and 7:
When those idiosyncratic anaphylactic events hit you in the arse in the Clinic, we'll see just how popular covalent inhibitors remain> anyone heard of penicillin allergies?

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern